Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

This is an open-label study to provide continued access to treatment for eligible participants who continue to derive clinical benefit as determined by the investigator from study intervention(s) in a Pfizer-sponsored palbociclib clinical study (Parent Study)